Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd., a biotech and medical-focused H-share issuer in Hong Kong, has updated details of its final dividend for the financial year ended 31 December 2025. The company continues to position itself as an income-distributing issuer in the healthcare space, offering shareholders regular cash returns alongside exposure to China’s medical and biotech growth.
The board declared a final dividend of RMB 0.6 per share for 2025, subject to shareholder approval on 29 May 2026, with the ex-dividend date set for 4 June 2026 and the Hong Kong dollar equivalent and payment date to be announced later. The announcement also clarifies Hong Kong share register arrangements and outlines withholding tax rates of 10% for non-resident enterprises and most non-resident individuals, and 20% for PRC resident individual investors accessing the H shares via Southbound Trading, defining after-tax cash outcomes for different shareholder groups.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a Hong Kong-listed company whose H shares trade under stock code 06826. The group operates in the biotechnology and medical sector, focusing on biopharmaceutical and related healthcare products for both domestic Chinese and international markets, serving institutional and individual investors through its H-share listing structure.
Average Trading Volume: 163,676
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.56B
Learn more about 6826 stock on TipRanks’ Stock Analysis page.